FDA clears Advaxis’ IND application to conduct Phase I trial of ADXS-HER2
In the first half of 2015, the company intends to start patient enrollment in the Phase I trial, which will be the first-in-human study of its lead Lm-LLO
XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule therapeutics targeting a G protein-coupled receptor (GPCR).
NovaMedica plans to begin marketing Benegast products in January 2015. Major products in the portfolio include: Benegast Reduflux, Benegast Redugas and Benegast Regulamine. Reduflux contains the proprietary compound
Both aspergillosis and mucormycosis are life-threatening fungal infections predominantly occurring in immunocompromised patients. The committee’s recommendation was based on data from the Cresemba development program, which included analyses
KX2-391 (KX01), a dual Src/pre-tubulin inhibitor, is a small molecule drug that has excellent skin penetration when formulated as a topical ointment. The pre-tubulin activity causes hyperproliferating cells